


## Aurora A inhibitor 2

Cat. No.:	HY-146037
CAS No.:	2412144-74-0
Molecular Formula:	C <sub>24</sub> H <sub>26</sub> N <sub>6</sub> O <sub>3</sub>
Molecular Weight:	446.5
Target:	Apoptosis; Aurora Kinase
Pathway:	Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Aurora A inhibitor 2 (Compound 16h) is a potent Aurora A kinase inhibitor with an IC <sub>50</sub> of 21.94 nM. Aurora A inhibitor 2 induces caspase-dependent apoptosis in MDA-MB-231 cells <sup>[1]</sup> .																	
<b>IC<sub>50</sub> &amp; Target</b>	Aurora A 21.94 nM (IC <sub>50</sub> )	Aurora B 273.18 nM (IC <sub>50</sub> )																
<b>In Vitro</b>	<p>Aurora A inhibitor 2 (Compound 16h) (0-20 μM, 48 h) shows potent antiproliferative activity against various human cancer cells, and inhibits colony formation<sup>[1]</sup>.</p> <p>Aurora A inhibitor 2 (0-4 μM, 24 h) inhibits the expression of phosphorylation of Aurora A and Histone H3 in a dose-dependent manner, and induces G2/M cell cycle arrest<sup>[1]</sup>.</p> <p>Aurora A inhibitor 2 (0-4 μM, 48 h) induces obvious apoptosis in MDA-MB-231 cells in a concentration-dependent manner<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Breast cancer MDA-MB231, prostate cancer PC3, and neuroblastoma SH-SY5Y cells</td> </tr> <tr> <td>Concentration:</td> <td>0-20 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Displayed potent antiproliferative activity with IC<sub>50</sub> values of 0.38 ± 0.08, 1.09 ± 0.24, and 0.77 ± 0.12 μM against MDA-MB-231, PC3, and SH-SY5Y cells.</td> </tr> </table> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>MDAMB-231</td> </tr> <tr> <td>Concentration:</td> <td>1, 2, and 4 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>A dose-dependent and significant reduction in the phosphorylation of Aurora A and Histone H3 was observed. Significantly increased the levels of cleaved caspase 3/9 and cleaved-PARP.</td> </tr> </table>		Cell Line:	Breast cancer MDA-MB231, prostate cancer PC3, and neuroblastoma SH-SY5Y cells	Concentration:	0-20 μM	Incubation Time:	48 h	Result:	Displayed potent antiproliferative activity with IC <sub>50</sub> values of 0.38 ± 0.08, 1.09 ± 0.24, and 0.77 ± 0.12 μM against MDA-MB-231, PC3, and SH-SY5Y cells.	Cell Line:	MDAMB-231	Concentration:	1, 2, and 4 μM	Incubation Time:	24 h	Result:	A dose-dependent and significant reduction in the phosphorylation of Aurora A and Histone H3 was observed. Significantly increased the levels of cleaved caspase 3/9 and cleaved-PARP.
Cell Line:	Breast cancer MDA-MB231, prostate cancer PC3, and neuroblastoma SH-SY5Y cells																	
Concentration:	0-20 μM																	
Incubation Time:	48 h																	
Result:	Displayed potent antiproliferative activity with IC <sub>50</sub> values of 0.38 ± 0.08, 1.09 ± 0.24, and 0.77 ± 0.12 μM against MDA-MB-231, PC3, and SH-SY5Y cells.																	
Cell Line:	MDAMB-231																	
Concentration:	1, 2, and 4 μM																	
Incubation Time:	24 h																	
Result:	A dose-dependent and significant reduction in the phosphorylation of Aurora A and Histone H3 was observed. Significantly increased the levels of cleaved caspase 3/9 and cleaved-PARP.																	

---

#### Cell Cycle Analysis<sup>[1]</sup>

Cell Line:	MDAMB-231
Concentration:	1, 2, and 4 $\mu$ M
Incubation Time:	24 h
Result:	Dose-dependently increased the and population of cells in the G2/M phase.

#### Apoptosis Analysis<sup>[1]</sup>

Cell Line:	MDAMB-231
Concentration:	1, 2, and 4 $\mu$ M
Incubation Time:	48 h
Result:	Induced obvious apoptosis in a concentration-dependent manner.

---

## REFERENCES

[1]. Chengcheng Fan, et al. Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition. Eur J Med Chem. 2020 Mar 15;190:112108.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA